stockrow
Friday 6 November 2026
Export ABVX’s income statement to Excel — free account
Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
86.01
1.83
+2.17%
Follow ABVX
Alert me
Abivax SA Sponsored ADR (ABVX) Current ratio
Abivax SA Sponsored ADR's current ratio at the end of the quarter to 30 June 2026 was 6.0×, down 2.8× from fiscal 2025 (8.7×). Over the past ten years it has ranged from 1.1× (fiscal 2019) to 8.7× (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 8.7× | 381.74% |
| FY2024 | 1.8× | (55.53%) |
| FY2023 | 4.1× | 262.60% |
| FY2022 | 1.1× | (52.50%) |
| FY2021 | 2.4× | 61.80% |
| FY2020 | 1.5× | 34.99% |
| FY2019 | 1.1× | (50.60%) |
| FY2018 | 2.2× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 6.0× | (27.67%) |
| Mar 2026 | 8.2× | (5.72%) |
| Dec 2025 | 8.7× | 11.24% |
| Sep 2025 | 7.9× | 925.97% |
| 10 more quarters | Free account |
Against its own ten years
Low 1.1×
High 8.7×
Ten-year median
2.0×
Current reading's percentile
100
Current ratio against peers
| Company | Current ratio |
|---|---|
| ORKA Oruka Therapeutics, Inc. compare | 38.5× |
| SYRE Spyre Therapeutics, Inc. compare | 27.4× |
| PRAX Praxis Precision Medicines, Inc. compare | 15.7× |
| ABVX Abivax SA Sponsored ADR | 6.0× |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | 5.9× |
| CYTK Cytokinetics, Incorporated compare | 3.4× |
| CORT Corcept Therapeutics Incorporated compare | 3.0× |
| RYTM Rhythm Pharmaceuticals, Inc. compare | 2.8× |
| AXSM Axsome Therapeutics, Inc. compare | 1.4× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)